RT Journal Article
SR Electronic
T1 CP-125 Evaluation of compliance and tolerability in treatment-naÏve patients suffering from idiopathic pulmonary fibrosis (IPF) and treated with pirfenidone
JF European Journal of Hospital Pharmacy
JO Eur J Hosp Pharm
FD British Medical Journal Publishing Group
SP A50
OP A50
DO 10.1136/ejhpharm-2015-000639.119
VO 22
IS Suppl 1
A1 F Capano
A1 C Lerda
A1 G Bandelli
A1 A Filieri
A1 C Albera
A1 D Ielo
YR 2015
UL http://ejhp.bmj.com/content/22/Suppl_1/A50.1.abstract
AB Background Idiopathic pulmonary fibrosis (IPF) is a rare disease with significant morbidity and mortality, with a 18.07/1,00,000 prevalence in our Region. Pirfenidone is an orally administered antifibrotic approved for the treatment of mild-to-moderate IPF.1 Pirfenidone is generally well tolerated, the most common side effects being on the gastro-intestinal (GI) tract and photosensitivity. However, side effects may partly offset treatment benefits and reduce compliance.Purpose To assess side effects (tolerability) and compliance in (treatment-naïve) IPF patients receiving pirfenidone.Material and methods In this prospective observational study, adherence was examined in patients treated between September 2013 and September 2014. Side effects and treatment compliance were recorded in a database. Adherence data were compared with the incidence of side effects occurring in the studied population.Results 34 IPF patients were evaluated during a 12 month follow-up.View this table:Abstract CP-125 Table 1 Comparison between prescribing and dispensing data showed that 19 (56%) of patients received 100% of the prescribed treatment, 22 (65%) received more than 90%, and only 3 (9%) received less than 50%.View this table:Abstract CP-125 Table 2 Side effects led to only 15% of patients discontinuing pirfenidone and were more evident during the first six months of treatment, as observed in clinical trials.Conclusion Tolerability: most side effects were manageable with supportive measures.Compliance: overall it was good. Closer pharmacist/physician interaction could further improve patient compliance.References and/or Acknowledgements 1 EMA summary of product characteristicsNo conflict of interest.